Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:ARE

Alexandria Real Estate Equities (ARE)

53.17
+0.40 (0.76%)
as of Jun 12, 2026, 8:00:00 pm Market Open.
21 watching
0
Investor Insights
star iconJun 11, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Alexandria Real Estate Equities (ARE-N) has faced significant challenges over the past year, with a sharp decline of 50% in its stock value. This downturn has been attributed largely to low tenant demand, which stems in part from a deteriorating IPO market that has affected its business operations. The company took drastic measures last year by slashing its dividend by 45%, indicating financial strain and a need to preserve liquidity during tough market conditions. The combination of these factors has raised concerns among investors and analysts about the company's future growth prospects and its ability to generate reliable returns. Overall, the outlook for ARE-N seems precarious as it navigates through a challenging economic landscape.

consensus icon
Consensus
Negative
valuation icon
Valuation
Overvalued
review icon
Similar
BioMed Realty, BMR
DON'T BUY

Lost 50% last year. Has been suffering from unit tenant demand for a while, partially from a weaker IPO market. Last year, they slashed their dividend by 45% at nearly 6%.

DON'T BUY

The largest US office REIT. Used to own it, still likes it alot for owning specialized spaces, like labs for biotechs. But this niche has problems, lacking IPOs and new companies. Is down 20% YTD.

BUY
Admires the management, but he doesn't like commercial office space now, but ARE's tenants are American biotech and life science companies, which carry the costs of. A lot of value here.
TOP PICK
The only REIT in health sciences, and is benefiting from demand to treat and cure COVID-19 and other diseases. Though considered an office REIT, she notes that many of its tenants cannot work from home. Rent collection is impressive at 99%, because life sciences are deemed essential. It leased 1 million sq. feet in Q2, consistent with prior quarters with rents 15% higher. Likes its assets, and it's a niche way to play this sector. (Analysts’ price target is $181.56)
PAST TOP PICK
(A Top Pick Dec 05/18, Up 33%) When he called it, ARE wasn't cheap. They hold life sciences properties, which is solid and lucrative (fuelled by R&D spending). They can raise rents by 20-30% annually with these companies, which means strong cash flow growth.
PAST TOP PICK
(A Top Pick Aug 16/18, Up 24%) One of the best capital compounders out there. They build life sciences buildings on campuses across the US. Biotech companies co-locate on these campuses, creating great opportunities. The fundamentals remain positive and he continues to hold it.
PAST TOP PICK
(A Top Pick Dec 05/18, Up 16%) They are a stellar company with a stellar management team. They are the dominant player of campuses to life sciences companies. It is important for these companies to be together to share ideas in an ecosystem. They have a free cash flow growth of north of 10%. He sees the company growing with their valuation. It is still a compelling investment opportunity.
TOP PICK
The entry point is great right now. They look to double their revenues by 2022 from $900 million today. They have a great balance sheet and management team. They hold assets in all the major US campuses. They are the curators of new biotech and big pharma real estate start-ups on and near these campuses. When a lease comes due, they can raise rents 30% or more. Yield 3%. (Analysts’ price target is $138.25)
PAST TOP PICK
(A Top Pick Aug 16/18, Down 3%) They hold assets in all the major US campuses. They are the curators of new biotech and big pharma real estate start-ups on and near these campuses. When a lease comes due, they can raise rents 30% or more.
TOP PICK

They specialize in technology and life-sciences clusters. Their tenants will be repatriation cash, so ARE's partnership with these tenants will create value and rent growth. (2.9% dividend yield)

Showing 1 to 10 of 10 entries
  • «
  • 1
  • »

Alexandria Real Estate Equities (ARE) Frequently Asked Questions

What is Alexandria Real Estate Equities stock symbol?

Alexandria Real Estate Equities is a American stock, trading under the symbol ARE (previously ARE-N on Stockchase) on the New York Stock Exchange (ARE). It is usually referred to as NYSE:ARE or ARE

Is Alexandria Real Estate Equities a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on ARE (previously ARE-N on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Alexandria Real Estate Equities.

Is Alexandria Real Estate Equities a good investment or a top pick?

Alexandria Real Estate Equities was recommended as a Top Pick by Joshua Varghese on 2018-08-16. Read the latest stock experts ratings for Alexandria Real Estate Equities.

Why is Alexandria Real Estate Equities stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Alexandria Real Estate Equities.

Is Alexandria Real Estate Equities worth watching?

Alexandria Real Estate Equities is followed by 21 investors on Stockchase and is a trending stock that is worth watching.

What is Alexandria Real Estate Equities stock price?

On 2026-06-12, Alexandria Real Estate Equities (ARE) stock closed at a price of $53.17.